Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)

OBJECTIVES: The objective of this study was to investigate the expression level of CD40 and its role in the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with rituximab-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). DESIGN AND METHOD...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Onco Targets Ther
Auteurs principaux: Song, Guoqi, Ni, Huiyun, Zou, Linqing, Wang, Shukui, Tian, Fuliang, Liu, Hong, Cho, William C
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2016
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4922817/
https://ncbi.nlm.nih.gov/pubmed/27382316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S96992
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires